Citations

Showing 10 of 108083 citations.

Mortality and Cerebrovascular Events After Heart Rhythm Disorder Management Procedures
Lee, Justin Z. , Ling, Jayna, Diehl, Nancy N. , Hodge, David O. , Padmanabhan, Deepak , Killu, Ammar M. , Madhavan, Malini , Cha, Yong‐Mei , Deshmukh, Abhishek , Shen, Win-Kuang, Friedman, Paul A. , Munger, Thomas M. , Asirvatham, Samuel J. , Packer, Douglas L. , Mulpuru, Siva K. , Kapa, Suraj , Asirvatham, Samuel J , Noseworthy, Peter A. , McLeod, Christopher J. , Srivathsan, Komandoor , Kusumoto, Fred

Mayo Clinic

Circulation | October 18, 2017 | Volume: 137 | Issue: 1 | Pages: 24-33

10.1161/circulationaha.117.030523 | PMID 29046320 Get It

Background: Recognition of rates and causes of hard, patient-centered outcomes of death and cerebrovascular events (CVEs) after heart rhythm disorder management (HRDM) procedures is an essential step for the development of quality improvement programs in electrophysiology laboratories. Our primary aim was to assess and characterize death and CVEs (stroke or transient ischemic attack) after HRDM procedures over a 17-year period. Methods: We performed a retrospective cohort study of all patients undergoing HRDM procedures between January 2000 and November 2016 at the Mayo Clinic. Patients from all 3 tertiary academic centers (Rochester, Phoenix, and Jacksonville) were included in the study. All in-hospital deaths and CVEs after HRDM procedures were identified and were further characterized as directly or indirectly related to the HRDM procedure. Subgroup analysis of death and CVE rates was performed for ablation, device implantation, electrophysiology study, lead extraction, and defibrillation threshold testing procedures. Results: A total of 48 913 patients (age, 65.7±6.6 years; 64% male) who underwent a total of 62 065 HRDM procedures were included in the study. The overall mortality and CVE rates in the cohort were 0.36% (95% confidence interval [CI], 0.31–0.42) and 0.12% (95% CI, 0.09–0.16), respectively. Patients undergoing lead extraction had the highest overall mortality rate at 1.9% (95% CI, 1.34–2.61) and CVE rate at 0.62% (95% CI, 0.32–1.07). Among patients undergoing HRDM procedures, 48% of deaths directly related to the HDRM procedure were among patients undergoing device implantation procedures. Overall, cardiac tamponade was the most frequent direct cause of death (40%), and infection was the most common indirect cause of death (29%). The overall 30-day mortality rate was 0.76%, with the highest being in lead extraction procedures (3.08%), followed by device implantation procedures (0.94%). Conclusions: Half of the deaths directly related to an HRDM procedure were among the patients undergoing device implantation procedures, with cardiac tamponade being the most common cause of death. This highlights the importance of the development of protocols for the quick identification and management of cardiac tamponade even in procedures typically believed to be lower risk such as device implantation.
Relationship of circulating spexin with markers of cardiovascular disease: a pilot study in adolescents with obesity
Kumar, Seema , Hossain, Jobayer , Javed, Asma , Balagopal, Prabhakaran , Kullo, Iftikhar J.

Mayo Clinic

Pediatric Obesity | October 18, 2017 | Volume: 13 | Issue: 6 | Pages: 374-380

10.1111/ijpo.12249 | PMID 29045048 Get It

SummaryPurposeSpexin, a novel peptide, has potential implications in obesity, satiety and energy homeostasis. The current study examined the relationship of spexin with various biomarkers of cardiovascular disease and endothelial function in adolescents with obesity.MethodsNineteen adolescents with obesity (age, 15.8 ± 1.7 years) were studied. Spexin, leptin and various cardiovascular disease biomarkers were measured. Endothelial function was assessed by high‐resolution Doppler ultrasonography of the right brachial artery.ResultsSpexin concentration (median [interquartile range] 0.38 ng/mL [0.29–0.59 ng/mL]) was inversely correlated (r = −0.50, P = 0.03) with leptin. When participants were clustered into two groups (‘high spexin and low leptin’ vs. ‘low spexin and high leptin’), the odds of having ‘low spexin and high leptin’ in participants with higher hs‐CRP (≥ 3 mg/L) were 12.25 times (95 per cent CI −1 to139, P = 0.026) higher than those of participants with lower hs‐CRP (<3 mg/L). Spexin levels, however, were not associated with measures of endothelial function.ConclusionsThe inverse association between spexin and leptin and the presence of higher concentrations of hs‐CRP in adolescents with obesity in the setting of ‘low spexin and high leptin’ suggest a potential role for spexin in the regulation of satiety and certain cardiovascular risk factors in children with obesity.
Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes
Fanaroff, Alexander C. , Manandhar, Pratik , Holmes, David R. , Harrison, J. Kevin , Thourani, Vinod H. , Mack, Michael J. , Sherwood, Matthew W. , Vemulapalli, Sreekanth , Douglas, Pamela S. , Hughes, G Chad, Jones, W Schuyler, Douglas, Pamela S , Cohen, David Jonathan , Hughes, George Chad , Jones, W. Schuyler , Fanaroff, Alexander C

Mayo Clinic

Circulation: Cardiovascular Interventions | October 17, 2017 | Volume: 10 | Issue: 10 | Pages: No page available

10.1161/circinterventions.117.005456 | PMID 29042398 Get It

Background— Peripheral artery disease (PAD) is associated with increased cardiovascular mortality, and PAD risk factors overlap with those for aortic stenosis. The prevalence and outcomes associated with PAD in a population undergoing transcatheter aortic valve replacement (TAVR) are unknown. Methods and Results— Using the Society of Thoracic Surgeons/Transcatheter Valve Therapy Registry linked to Medicare claims data, we identified patients ≥65 years old undergoing TAVR from 2011 to 2015. We calculated hazard ratios for 1-year adverse outcomes, including mortality, readmission, and bleeding, for patients with PAD compared with those without, adjusting for baseline characteristics and postprocedure medications. Analyses were performed separately by access site (transfemoral and nontransfemoral). Of 19 660 patients undergoing transfemoral TAVR, 4810 (24.5%) had PAD; 3730 (47.9%) of 7780 patients undergoing nontransfemoral TAVR had PAD. In both groups, patients with PAD were significantly more likely to have coronary and carotid artery diseases. At 1-year follow-up, patients with PAD undergoing TAVR via transfemoral access had a higher incidence of death (16.8% versus 14.4%; adjusted hazard ratio, 1.14; P =0.01), readmission (45.5% versus 42.1%; hazard ratio, 1.11; P <0.001), and bleeding (23.1% versus 19.7%; hazard ratio, 1.18; P <0.001) compared with patients without PAD. Patients with PAD undergoing TAVR via nontransfemoral access did not have significantly higher rates of 1-year mortality or readmission compared with patients without PAD. Conclusions— PAD is common among patients undergoing commercial TAVR via transfemoral and nontransfemoral access. Among patients undergoing transfemoral TAVR, PAD is associated with a higher incidence of 1-year adverse outcomes compared with absence of PAD. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01737528.
A Prospective Study of the Causes of Bruises in Premobile Infants
Tayama, Tricia Michels, Strickler, Leslie , Johnson, Lee A., Kolhatkar, Gauri, DeRidder, Catherine A. , Matthews, Dana C., Sidbury, Robert , Feldman, Kenneth W. , Johnson, Lee A., Taylor, James Arnold

Mayo Clinic

Pediatric Emergency Care | October 17, 2017 | Volume: 36 | Issue: 2 | Pages: e43-e49

10.1097/pec.0000000000001311 | PMID 29040244 Get It

Objective This study had 2 objectives. First, to determine the behavior of physicians evaluating premobile infants with bruises. Second, and most importantly, to learn whether infants with unexplained bruising who had been initially evaluated by primary care and emergency department (ED) physicians are as likely to have their bruises attributed to child abuse as those children evaluated by child abuse physicians. Methods Primary care, ED, and child abuse pediatricians (CAPs) in King County, Washington, San Mateo, Calif, Albuquerque, NM, La Crosse, Wis, and Torrance, Calif prospectively identified and studied infants younger than 6 months with less than 6 bruises, which were judged by the evaluating clinician to be explained or unexplained after their initial clinical examination. Results Between March 1, 2010, and March 1, 2017, 63 infants with initially explained and 46 infants with initially unexplained bruises were identified. Infants with unexplained bruises had complete coagulation and abuse evaluations less frequently if they were initially identified by primary care pediatricians or ED providers than by CAPs. After imaging, laboratory, and follow-up, 54.2% (26) of the infants with initially unexplained bruises, including 2 who had been initially diagnosed with accidental injuries, were diagnosed as abused. Three (6.2%) infants had accidental bruising, 6 (12.4%) abuse mimics, 1 (2.5%) self-injury, 1 (2.5%) medical injury, and 11 (22.9%) remained of unknown causation. None had causal coagulation disorders. A total of 65.4% of the 26 abused infants had occult injuries detected by their imaging and laboratory evaluations. Six (23.1%) abused infants were not diagnosed until after they sustained subsequent injuries. Three (11.5%) were recognized abused by police investigation alone. Thirty-eight percent of the abused, bruised infants had a single bruise. Clinicians' estimates of abuse likelihood based on their initial clinical evaluation were inaccurate. Primary care, ED, and child abuse physicians identified abused infants at similar rates. Conclusions More than half of premobile infants with initially unexplained bruises were found to be abused. Abuse was as likely for infants identified by primary care and ED providers as for those identified by CAPs. Currently, physicians often do not obtain full abuse evaluations in premobile infants with unexplained bruising. Their initial clinical judgment about abuse likelihood was inadequate. Bruised infants often have clinically occult abusive injuries or will sustain subsequent serious abuse. Bruised infants should have full abuse evaluations and referral for Protective Services and police assessments.
Fatty Pancreas
Majumder, Shounak , Philip, N, Takahashi, Naoki , Levy, Michael J. , Singh, Vijay , Chari, Suresh T. , Majumder, Shounak , Singh, Vijay P , Levy, Michael J. , Takahashi, Naoki , Chari, Suresh T

Mayo Clinic

Pancreas | October 17, 2017 | Volume: 46 | Issue: 10 | Pages: 1251-1258

10.1097/mpa.0000000000000941 | PMID 29040194 Get It

AbstractThe metabolic consequences of visceral fat deposition are well known, and the presence of intrapancreatic fat (IPF) has been recognized for decades. However, our knowledge about the distribution of fat in the pancreas and its clinical implications is in a nascent stage. Various terms have been proposed to describe IPF; for the purpose of this narrative review, we chose the general termfatty pancreas. Herein, we describe the radiologic, endoscopic, and histopathologic aspects of diagnosing fatty pancreas and provide an overview of the diseases associated with this condition. Our purpose is to highlight diagnostic challenges and identify specific clinical questions that would benefit from further study. As evident in this review, IPF is associated with various metabolic diseases, pancreatitis, pancreatic cancer, and precancer—yet establishing causality needs careful, further study.
Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression
Petrova‐Drus, Kseniya , Chiu, April , Margolskee, Elizabeth , Barouk-Fox, Sharon, Geyer, Julia T. , Orazi, Attilio , Petrova-Drus, Kseniya , Doǧan, Ahmet , Orazi, Attilio

Mayo Clinic

Oncotarget | October 17, 2017 | Volume: 8 | Issue: 61 | Pages: 103274-103282

10.18632/oncotarget.21870 | PMID 29262560 Get It

Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data
Yin, Jun , Mandrekar, Sumithra J. , Paolettí, Xavier , Sargent, Daniel J.

Mayo Clinic

Clinical Trials | October 17, 2017 | Volume: 14 | Issue: 6 | Pages: 611-620

10.1177/1740774517723829 | PMID 28764555 Get It

Background: Phase I trials are designed to determine the safety, tolerability, and recommended phase 2 dose of therapeutic agents for subsequent testing. The dose-finding paradigm has thus traditionally focused on identifying the maximum tolerable dose of an agent or combination therapy under the assumption that there is a non-decreasing relationship between dose–toxicity and dose–efficacy. The dose is typically determined based on the probability of severe toxicity observed during the first treatment cycle. A novel endpoint, the total toxicity profile, was previously developed to account for the multiple toxicity types and grades experienced in the first cycle. More recently, this was extended to a repeated measures design based on the total toxicity profile to account for longitudinal toxicities over multiple treatment cycles in the absence of within-patient correlation. Methods: In this work, we propose to extend the design in the presence of within-patient correlation. Furthermore, we provide a framework to detect a toxicity time trend (toxicity increasing, decreasing, or stable) over multiple treatment cycles. We utilize a linear mixed model in the Bayesian framework, with the addition of Bayesian risk functions for decision-making in dose assignment. Results: The performance of this design was evaluated using simulation studies and real data from a phase I trial. We demonstrated that using available toxicity data from all cycles of treatment improves the accuracy of maximum tolerated dose identification and allows for the detection of a time trend. The performance is consistent regardless of the strength of the within-patient correlation. In addition, the use of a quasi-continuous total toxicity profile score significantly increased the power to detect time trends compared to when binary data only were used. Conclusion: The increased interest in molecularly targeted agents and immunotherapies in oncology necessitates innovative phase I study designs. Our proposed framework provides a tool to tackle some of the challenges presented by these novel agents, specifically through the ability to understand patterns of toxicity over time, which is important in the cases of cumulative or late toxicities.
NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma
McWilliams, Robert R. , Allred, Jacob B., Slostad, Jessica , Katipamula, Rajini, Dronca, Roxana , Rumilla, Kandelaria M., Erickson, Lori A. , Bryce, Alan H. , Kottschade, Lisa A. , King, David M. , Leitch, John M., Slostad, Jessica A, Dronca, Roxana S., Bryce, Alan H , McWilliams, Robert R , Joseph, Richard W. , Markovic, Svetomir N. , Erickson, Lori A

Mayo Clinic

Cancer | October 17, 2017 | Volume: 124 | Issue: 3 | Pages: 537-545

10.1002/cncr.31072 | PMID 29044496 Get It

BACKGROUNDDespite the success of immune checkpoint and targeted therapy, many patients with melanoma ultimately require further treatment. The combination of carboplatin, paclitaxel, and bevacizumab (CPB) has demonstrated promising activity in a single‐arm study. In the current study, the authors performed a randomized phase 2 study to confirm efficacy and to determine whether adding everolimus would increase the activity of the combination.METHODSThrough the North Central Cancer Treatment Group, a total of 149 patients with unresectable AJCC 6th edition stage IV melanoma were randomized from May 2010 to May 2014 to either CPB or CPB with everolimus (CPBE). The primary endpoint was progression‐free survival (PFS), with secondary endpoints of overall survival (OS), response rate, and tolerability.RESULTSThe CPB and CPBE treatment arms were balanced with regard to age (median age: 59 years vs 58 years) and high lactate dehydrogenase (48% vs 51%), but were unbalanced with regard to sex (male sex: 72% vs 55%; P = .03). Overall, there was no difference noted with regard to PFS, with a median PFS of 5.6 months for CPB versus 5.1 months for CPBE (hazard ratio [HR], 1.14; 95% confidence interval [95% CI], 0.81‐1.62 [P = .44]), or for OS, with a median OS of 14.5 months for CPB versus 10.8 months for CPBE (HR, 1.16; 95% CI, 0.84‐1.84). The confirmed response rate was 13% for CPB and 23% for CPBE (P = .13). Toxicity was higher for CPBE compared with CPB (83% for grade 3 + and 14% for grade 4 + vs 63% for grade 3 + and 11% for grade 4+, respectively) (toxicities were graded using the Cancer Therapy Evaluation Program of the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]). Common grade 3 + toxicities were neutropenia, leukopenia, and fatigue, which occurred in both treatment arms with comparable frequency.CONCLUSIONSBoth experimental arms demonstrated activity, with a PFS of >5 months. However, the addition of everolimus to CPB failed to improve outcomes, with increased toxicity noted. These findings replicate the moderate antitumor activity of CPB, with future development possibly in combination with targeted or immunotherapy. Cancer 2018;124:537‐45. © 2017 American Cancer Society.
Snapping Pes Anserinus and the Diagnostic Utility of Dynamic Ultrasound
Hernandez, Lorenzo O., Montero, Daniel , Montero, Daniel P, Shapiro, Shane A.

Mayo Clinic

Journal of Clinical Imaging Science | October 17, 2017 | Volume: 7 | Issue: No issue available | Pages: 39

10.4103/jcis.jcis_45_17 | PMID 29142781 Get It

Snapping pes anserinus syndrome is an often encountered cause of medial knee snapping. It results from impingement and translation of the gracilis tendon or semitendinosus tendon over the osseous structures of the knee during active flexion and extension. Ultrasonography is often the diagnostic imaging test of choice in cases of mechanical snapping. We report 2 cases of painful snapping pes anserinus and highlight the value of dynamic ultrasound in making an accurate diagnosis so as to direct care.
Right Heart Dysfunction and Failure in Heart Failure with Preserved Ejection Fraction: Mechanisms and Management. Position Statement on Behalf of the Heart Failure Association of the European Society of Cardiology
Gorter, Thomas M. , Veldhuisen, Dirk J. van , Borlaug, Barry A. , Čelutkienė, Jelena , Crespo‐Leiro, María G. , Guazzi, Marco , Harjola, Veli‐Pekka, Heymans, Stéphane , Hill, Loreena , Lund, Lars H. , Mebazaa, Alexandre , Mueller, Christian, Paulus, Walter J. , Pieske, Burkert , Piepoli, Massimo , Seferović, Petar , Solomon, Scott D. , Shah, Sanjiv J. , Wachter, Rolf , Tschöpe, Carsten , Boer, Rudolf A. de , de Boer, Rudolf A , Borlaug, Barry A , Shah, Sanjiv J , Heymans, Stephane , Bauersachs, Johann , Coats, Andrew J.S. , Harjola, Veli‐Pekka , Lainščak, Mitja , Lam, Carolyn S.P. , Lyon, Alexander R. , Ruschitzka, Frank T. , Rutten, Frans Hendrik , Solomon, Scott David , Triposkiadis, Filippos K. , Tschöpe, Carsten , Celutkiene, Jelena , Crespo-Leiro, Maria Generosa

Mayo Clinic

European Journal of Heart Failure | October 17, 2017 | Volume: 20 | Issue: 1 | Pages: 16-37

10.1002/ejhf.1029 | PMID 29044932 Get It

Abstract There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.